Investigational Drug Information for Tivantinib
✉ Email this page to a colleague
What is the drug development status for Tivantinib?
Tivantinib is an investigational drug.
There have been 28 clinical trials for Tivantinib.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 11th 2011.
The most common disease conditions in clinical trials are Carcinoma, Lung Neoplasms, and Carcinoma, Hepatocellular. The leading clinical trial sponsors are National Cancer Institute (NCI), Daiichi Sankyo, Inc., and Daiichi Sankyo Inc.
Summary for Tivantinib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 788 |
| WIPO Patent Applications | 615 |
| Japanese Patent Applications | 238 |
| Clinical Trial Progress | Phase 3 (2011-01-11) |
| Vendors | 70 |
Recent Clinical Trials for Tivantinib
| Title | Sponsor | Phase |
|---|---|---|
| TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES) | Istituto Oncologico Veneto IRCCS | Phase 2 |
| Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment | Medpace, Inc. | Phase 1 |
| Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment | Daiichi Sankyo Inc. | Phase 1 |
Clinical Trial Summary for Tivantinib
Top disease conditions for Tivantinib
Top clinical trial sponsors for Tivantinib
US Patents for Tivantinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
